|
US581916A
(en)
|
|
1897-05-04 |
|
Harvester |
|
US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
|
US4342776A
(en)
|
1979-11-05 |
1982-08-03 |
Merck & Co., Inc. |
4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
|
|
US4399276A
(en)
|
1981-01-09 |
1983-08-16 |
Kabushiki Kaisha Yakult Honsha |
7-Substituted camptothecin derivatives
|
|
US4473692A
(en)
|
1981-09-04 |
1984-09-25 |
Kabushiki Kaisha Yakult Honsha |
Camptothecin derivatives and process for preparing same
|
|
JPS5839685A
(ja)
|
1981-09-04 |
1983-03-08 |
Yakult Honsha Co Ltd |
新規なカンプトテシン誘導体及びその製造法
|
|
JPS58154582A
(ja)
|
1982-03-10 |
1983-09-14 |
Yakult Honsha Co Ltd |
新規なカンプトテシン誘導体およびその製造法
|
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
|
JPS6019790A
(ja)
|
1983-07-14 |
1985-01-31 |
Yakult Honsha Co Ltd |
新規なカンプトテシン誘導体
|
|
EP0184365B1
(en)
|
1984-12-04 |
1993-08-04 |
Eli Lilly And Company |
Improvements in the treatment of tumors in mammals
|
|
US5223608A
(en)
|
1987-08-28 |
1993-06-29 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
|
US5004758A
(en)
|
1987-12-01 |
1991-04-02 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
|
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Acylhydrazone derivatives of anthracycline and methods for their preparation
|
|
DK0418099T3
(da)
|
1989-09-15 |
2002-04-02 |
Res Triangle Inst |
Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6407115B1
(en)
|
1991-01-16 |
2002-06-18 |
Daiichi Pharmaceutical Co., Ltd. |
Hexa-cyclic compound
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
EP0563475B1
(en)
|
1992-03-25 |
2000-05-31 |
Immunogen Inc |
Cell binding agent conjugates of derivatives of CC-1065
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
FR2707988B1
(fr)
|
1993-07-21 |
1995-10-13 |
Pf Medicament |
Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
|
|
DK0871490T3
(da)
|
1995-12-22 |
2003-07-07 |
Bristol Myers Squibb Co |
Forgrenede hydrazonlinkere
|
|
EP1053752A1
(en)
|
1998-02-10 |
2000-11-22 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Preparations with controlled release
|
|
AU756796B2
(en)
|
1998-10-16 |
2003-01-23 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Combination therapy with VIP antagonist
|
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
|
CA2388063C
(en)
|
1999-11-24 |
2010-06-08 |
Immunogen, Inc. |
Cytotoxic agents comprising taxanes and their therapeutic use
|
|
WO2001058479A1
(en)
|
2000-02-08 |
2001-08-16 |
The Penn State Research Foundation |
Immunotherapy using interleukin 13 receptor subunit alpha 2
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US7771951B2
(en)
|
2001-12-03 |
2010-08-10 |
Amgen Fremont Inc. |
Antibody categorization based on binding characteristics
|
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
|
US6756397B2
(en)
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
BR0313197A
(pt)
|
2002-08-02 |
2005-08-09 |
Immunogen Inc |
Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
|
|
DE60336149D1
(de)
|
2002-08-16 |
2011-04-07 |
Immunogen Inc |
Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
|
|
AU2003279842A1
(en)
|
2002-10-04 |
2004-05-04 |
Microchips, Inc. |
Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
CA2672581A1
(en)
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
|
|
WO2008130158A1
(en)
|
2007-04-19 |
2008-10-30 |
Dong-A Pharmaceutical. Co., Ltd |
A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
|
|
EP2241578B1
(en)
|
2008-01-11 |
2016-04-20 |
The University of Tokyo |
Anti-cldn6 antibody
|
|
NZ610239A
(en)
|
2008-04-30 |
2014-11-28 |
Immunogen Inc |
Cross-linkers and their uses
|
|
SG189817A1
(en)
|
2008-04-30 |
2013-05-31 |
Immunogen Inc |
Potent conjugates and hydrophilic linkers
|
|
US8025098B2
(en)
|
2008-06-18 |
2011-09-27 |
Xyleco, Inc. |
Processing hydrocarbons
|
|
ES3000111T3
(en)
|
2009-02-13 |
2025-02-27 |
Immunomedics Inc |
Intermediates for preparing conjugates with an intracellularly-cleavable linkage
|
|
DK3305813T3
(da)
|
2009-11-11 |
2020-04-20 |
Astellas Pharma Inc |
Antistoffer, der er specifikke for claudin 6 (cldn6)
|
|
US8840902B2
(en)
|
2010-03-16 |
2014-09-23 |
Biontech Ag |
Tumor vaccination involving a humoral immune response against self-proteins
|
|
EP2404936A1
(en)
*
|
2010-07-06 |
2012-01-11 |
Ganymed Pharmaceuticals AG |
Cancer therapy using CLDN6 target-directed antibodies in vivo
|
|
ES2989943T3
(es)
*
|
2011-05-13 |
2024-11-28 |
Astellas Pharma Inc |
Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
|
|
ES2773710T3
(es)
|
2012-10-11 |
2020-07-14 |
Daiichi Sankyo Co Ltd |
Enlazadores para conjugados de anticuerpo - fármaco
|
|
WO2014075697A1
(en)
*
|
2012-11-13 |
2014-05-22 |
Biontech Ag |
Agents for treatment of claudin expressing cancer diseases
|
|
JP6499079B2
(ja)
*
|
2012-11-13 |
2019-04-10 |
バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ |
クローディンを発現するガン疾患を処置するための剤
|
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
|
RU2016122041A
(ru)
|
2013-11-06 |
2017-12-11 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые анти-клаудин антитела и способы их применения
|
|
PT3514172T
(pt)
|
2014-04-01 |
2020-04-21 |
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh |
Imunorrecetores específicos de claudina-6 e epítopos de células t
|
|
ES2875274T3
(es)
|
2015-11-02 |
2021-11-10 |
Hoffmann La Roche |
Procedimientos de preparación de formas fucosiladas y afucosiladas de una proteína
|
|
RU2018124319A
(ru)
|
2015-12-04 |
2020-01-09 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые антитела к клаудину и способы их применения
|
|
NO20210351A1
(en)
|
2017-09-18 |
2021-03-18 |
Univ California |
Claudin6 antibodies and methods of treating cancer
|
|
US20220177583A1
(en)
|
2019-03-20 |
2022-06-09 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
|
DK3941946T3
(da)
|
2019-03-20 |
2025-03-24 |
Univ California |
Claudin-6-antistoffer og lægemiddelkonjugater
|